The US Food and Drug Administration (FDA) has granted approval to French biopharmaceutical company Ipsen for Bylvay (odevixibat) for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) patients aged 12 months and older. This once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) primarily acts in the small intestine and has minimal systemic exposure. Already […]
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to propel the development of its lead drug, Maralixibat, aimed at treating rare cholestatic liver diseases. The round was spearheaded by New Enterprise Associates (NEA) and saw participation from other notable investors including Deerfield Management, Frazier Healthcare Partners, […]
